Sudeep Pharma IPO to open for subscription on Nov 21; check price band, GMP, other key details

Sudeep Pharma IPO opens for subscription on November 21. 

Sudeep Pharma initial public offering (IPO) will open for public subscription in the primary market November 21. The Vadodara-based company has fixed the price band at Rs 563-593 per equity share for the Rs 895 crore initial public offering.

The IPO will conclude on November 25, and bidding for anchor investors will open for a day on November 20.

Sudeep Pharma IPO GMP Today price

According to platforms tracking the grey market activities, the shares of Sudeep Pharma are commanding a GMP of over 19 percent in the unregulated market. Investorgain quoted a GMP of Rs 115 for the shares of the company, indicating a listing gain of 19.39 percent.

The net proceeds from the fresh issue to the tune of Rs 75.81 crore will be for capital expenditure towards procurement of machinery for its production line located at Nandesari Facility 1, Gujarat and general corporate purposes.

Sudeep Pharma is a technology-led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and is dedicated to contributing to the global healthcare ecosystem.

The company is one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors, in terms of production capacity with a combined annual available manufacturing capacity of 72,246 metric tons, as of June 30, 2025, as per F&S report.

It has served over 1,100 customers, and has built longstanding relationships with marquee customers including Pfizer Inc, Mankind Pharma, Merck Group, Aurobindo Pharma, Cadila Pharmaceutical, IMCD Asia Pte Ltd, and Danone SA.

Shares of the company are proposed to be listed on the BSE and NSE on November 28, while the allotment is expected by November 26.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.